Our lead cancer-selective immunotherapy product is under investigation in a Phase 3 clinical trial, Toca 5, for patients with brain cancer.
Tocagen believes the immune system can be safely activated to fight the patient’s cancer. Driven by this vision, we are developing first-in-class, broadly applicable, product candidates designed to activate a patient’s immune system against their own cancer from within.
Tocagen has developed a new product candidate for cancer, Toca 521. This investigational compound targets PD-L1 from within, potentially overcoming limitations of available checkpoint inhibitors and improving patient outcomes.
Tocagen is advancing a broadly applicable, cancer-selective gene therapy platform that is designed to deliver therapeutic genes into the DNA of cancer cells and activate a patient’s immune system against their own cancer from within.
Tocagen is committed to fighting cancer. We have multiple clinical trials ongoing with our lead cancer-selective gene therapy product candidate, Toca 511 & Toca FC.
Tocagen is a clinical-stage, cancer-selective gene therapy company focused on developing first-in-class, broadly-applicable product candidates designed to activate a patient’s immune system against their own cancer from within.
Tocagen Reports Second Quarter 2018 Financial and Business Results
Interested in following our progress? Subscribe below.